Gautret, et al. (2020) [33]  Uncontrolled, non-comparative, observational study80 mildly infected patients  600 mg/day HCQ per 10 days + 500 mg AZM on day 1 followed by 250 mg/day for 4 daysFor patients with pneumonia and NEWS score ≥ 5 ceftriaxone was added to HCQ/AZM treatment  On day 7, nasopharyngeal viral load tested by qPCR was negative for 83% of patients and for 93% of patients at day 8.At day 5 in 97.5% of patients, virus cultures of the respiratory sample were negative.After 10 days only 2 patients were contagious.  One patient died.Six patients had GI side effects (2 nausea or vomiting and 4 diarrhea)One patient had blurred vision.  Six patients from previous trials by Gautret et al. were also included in this study. No analytical approach has been made to take into account possible factors of confusion, including in particular the severity of the disease.